{"drugs":["Pneumococcal Vaccine Polyvalent","Pneumovax 23","Pnu-Imune 23"],"mono":{"0":{"id":"928155-s-0","title":"Generic Names","mono":"Pneumococcal Vaccine Polyvalent"},"1":{"id":"928155-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928155-s-1-4","title":"Adult Dosing","mono":"<ul><li>when pneumococcal 13-valent vaccine is also indicated, that vaccine should be given first<\/li><li><b>Pneumococcal vaccination, 23-Valent vaccine:<\/b> (50 years or older) administer 1 dose IM\/SUBQ (manufacturer dosing)<\/li><li><b>Pneumococcal vaccination, 23-Valent vaccine:<\/b> (Revaccination) Administer 1 dose (0.5 mL) IM\/SUBQ; routine revaccination of immunocompetent persons is not recommended<\/li><\/ul>"},"1":{"id":"928155-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>all recommended pneumococcal 13-valent vaccine doses should be administered prior to pneumococcal 23 valent vaccine, if possible; minimum age for vaccination is 2 years<\/li><li><b>Pneumococcal vaccination, 23-Valent vaccine:<\/b> (2 years or older at increased risk) Administer 1 dose (0.5 mL) IM\/SUBQ<\/li><\/ul>"},"3":{"id":"928155-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Pneumococcal vaccination, 23-Valent vaccine<br\/>"}}},"3":{"id":"928155-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928155-s-3-9","title":"Contraindications","mono":"anaphylactic\/anaphylactoid or severe allergic reaction to any component of the pneumococcal vaccine <br\/>"},{"id":"928155-s-3-10","title":"Precautions","mono":"<ul><li>acute illness, moderate or severe; defer vaccination<\/li><li>American Indians or Alaskan natives; routine vaccination not recommended; may vaccinate if reside in a region with increased risk of invasive disease<\/li><li>antibiotic prophylaxis against pneumococcal infection; vaccine does not replace the need for penicillin or other antibiotic prophylaxis<\/li><li>cardiovascular function, severely compromised; a systemic reaction would pose a significant risk<\/li><li>cerebrospinal fluid leakage, chronic, resulting from congenital lesions, skull fractures, or neurosurgical procedures; vaccine may not be effective in preventing pneumococcal meningitis<\/li><li>concurrent administration of live zoster vaccine (Zostavax(R)); reduced immune response to zoster vaccine has been reported; consider administrating the 2 vaccines at least 4 weeks apart<\/li><li>immunocompromised, including those receiving immunosuppressive therapy; expected antibody response may not be obtained<\/li><li>pulmonary function, severely compromised; a systemic reaction would pose a significant risk<\/li><li>report adverse reactions to VAERS at 1-800-822-7967 or at www.vaers.hhs.gov<\/li><\/ul>"},{"id":"928155-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B2 (AUS)<\/li><\/ul>"},{"id":"928155-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk is minimal.<br\/>"}]},"4":{"id":"928155-s-4","title":"Drug Interactions","sub":{"1":{"id":"928155-s-4-14","title":"Major","mono":"<ul><li>Cyclosporine (theoretical)<\/li><li>Varicella Virus Vaccine (established)<\/li><\/ul>"},"2":{"id":"928155-s-4-15","title":"Moderate","mono":"<ul>Rituximab (probable)<\/ul>"}}},"5":{"id":"928155-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (16.4% to 34.5%), Injection site edema, Injection site induration, Injection site pain, Injection site reaction<\/li><li><b>Musculoskeletal:<\/b>Myalgia (11.9% to 17.3%)<\/li><li><b>Neurologic:<\/b>Asthenia, Headache (17.6% to 18.1%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Hemolytic anemia, Thrombocytopenia<\/li><li><b>Immunologic:<\/b>Anaphylactoid reaction, Serum sickness due to drug<\/li><li><b>Neurologic:<\/b>Guillain-Barr  syndrome<\/li><li><b>Other:<\/b>Angioedema, Fever, Greater than 102 degrees F<\/li><\/ul>"},"6":{"id":"928155-s-6","title":"Drug Name Info","sub":{"0":{"id":"928155-s-6-17","title":"US Trade Names","mono":"<ul><li>Pneumovax 23<\/li><li>Pnu-Imune 23<\/li><\/ul>"},"2":{"id":"928155-s-6-19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"928155-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"928155-s-7","title":"Mechanism Of Action","mono":"Pneumococcal capsular polysaccharide antigens induce type-specific antibodies that enhance opsonization, phagocytosis, and killing of pneumococci by leukocytes and other phagocytic cells .<br\/>"},"9":{"id":"928155-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>administer subQ or IM; do not give IV or intradermally; do not mix with other vaccines<\/li><li>23-valent pneumococcal vaccine may be administered at the same time as influenza vaccine by separate injection in the other arm.<\/li><\/ul><\/li><li><b>Intramuscular<\/b><br\/>preferred injection site is in the deltoid muscle or lateral mid-thigh<br\/><\/li><\/ul>"},"13":{"id":"928155-s-13","title":"Clinical Teaching","mono":"<ul><li>If patient is taking penicillin as prophylaxis against pneumococcal infection, advise patient to continue penicillin therapy after vaccination, unless otherwise directed by healthcare professional.<\/li><li>This drug may cause fever or soreness, erythema, swelling, or induration at injection site.<\/li><li>Advise patient to report angioedema (deep swelling around eyes and lips and sometimes hands and feet) or signs\/symptoms of hemolytic anemia or thrombocytopenia.<\/li><\/ul>"}}}